Stay updated with breaking news from Complement Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board Exonate Ltd., a biotechnology company developing novel
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director. Rafiq brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.
EXONATE APPOINTS DR RAFIQ HASAN AS NON-EXECUTIVE DIRECTOR Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens
In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.
A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.